Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.16 Insider Own15.15% Shs Outstand53.80M Perf Week7.99%
Market Cap57.75M Forward P/E- EPS next Y-1.82 Insider Trans-0.20% Shs Float46.23M Perf Month-12.40%
Income-116.52M PEG- EPS next Q-0.47 Inst Own52.34% Short Float / Ratio7.40% / 5.51 Perf Quarter-55.83%
Sales21.23M P/S2.72 EPS this Y-30.19% Inst Trans-0.37% Short Interest3.42M Perf Half Y-65.70%
Book/sh1.57 P/B0.67 EPS next Y11.84% ROA-70.86% Target Price11.50 Perf Year-91.02%
Cash/sh1.45 P/C0.73 EPS next 5Y- ROE-86.16% 52W Range0.90 - 12.81 Perf YTD-90.13%
Dividend- P/FCF- EPS past 5Y3.05% ROI-126.02% 52W High-91.73% Beta0.81
Dividend %- Quick Ratio4.25 Sales past 5Y400.85% Gross Margin62.62% 52W Low17.78% ATR0.11
Employees106 Current Ratio4.40 Sales Q/Q-55.00% Oper. Margin-566.29% RSI (14)44.74 Volatility10.43% 10.57%
OptionableYes Debt/Eq0.09 EPS Q/Q-19.82% Profit Margin-548.95% Rel Volume0.95 Prev Close0.97
ShortableYes LT Debt/Eq0.08 EarningsNov 13 AMC Payout- Avg Volume620.42K Price1.06
Recom1.33 SMA20-3.16% SMA50-19.30% SMA200-69.41% Volume590,600 Change9.63%
Date Action Analyst Rating Change Price Target Change
Mar-08-23Downgrade BofA Securities Neutral → Underperform $13 → $6
Mar-08-22Upgrade JP Morgan Neutral → Overweight $17 → $20
Nov-01-21Resumed Canaccord Genuity Buy $33
Aug-03-21Initiated JP Morgan Neutral $16
Apr-21-20Reiterated H.C. Wainwright Buy $30 → $33
Aug-12-19Reiterated H.C. Wainwright Buy $31 → $30
May-29-19Reiterated Laidlaw Buy $26 → $32
Feb-06-19Resumed Jefferies Buy $22
Jan-15-19Initiated BofA/Merrill Neutral $19
Sep-21-18Initiated Cantor Fitzgerald Overweight
Nov-14-23 11:04AM
Nov-13-23 06:00PM
11:38AM Loading…
Nov-09-23 11:38AM
Nov-06-23 10:00AM
Nov-02-23 07:00AM
Oct-23-23 07:00AM
Sep-25-23 07:00AM
Sep-05-23 07:00AM
Aug-10-23 02:53AM
Aug-08-23 05:54AM
Aug-07-23 05:15PM
04:01PM Loading…
Aug-03-23 07:00AM
Aug-02-23 07:00AM
Jul-24-23 07:00AM
Jun-14-23 01:37PM
Jun-13-23 06:30AM
Jun-02-23 06:46PM
Jun-01-23 07:00AM
May-30-23 06:34PM
May-25-23 06:40AM
May-18-23 04:53PM
May-16-23 11:02AM
May-15-23 05:15PM
04:01PM Loading…
May-04-23 09:38AM
May-01-23 07:00AM
Apr-26-23 08:00PM
Apr-10-23 07:00AM
Apr-07-23 08:41AM
Mar-14-23 07:00AM
Mar-11-23 07:19AM
Mar-08-23 06:59AM
Mar-07-23 10:46AM
Mar-06-23 07:39PM
Feb-27-23 10:00AM
Feb-21-23 07:00AM
Feb-15-23 05:11AM
Feb-08-23 05:00PM
Jan-17-23 07:00AM
Jan-03-23 07:00AM
Dec-29-22 05:53AM
Nov-29-22 07:30AM
Nov-09-22 06:08AM
Nov-07-22 05:35PM
Nov-04-22 08:46AM
Nov-03-22 07:00AM
Nov-02-22 10:01AM
Oct-31-22 10:00AM
Oct-30-22 08:51AM
Oct-24-22 07:00AM
Oct-18-22 09:55AM
Oct-10-22 04:05PM
Sep-28-22 07:00AM
Sep-20-22 09:47AM
Sep-12-22 07:00AM
Sep-08-22 02:27PM
Sep-06-22 07:00AM
Aug-24-22 07:00AM
Aug-22-22 07:00AM
Aug-19-22 01:00AM
Aug-08-22 05:15PM
Aug-04-22 08:48AM
Aug-03-22 07:00AM
Aug-01-22 04:01PM
Jul-28-22 09:14AM
Jul-22-22 06:39AM
Jun-30-22 10:19AM
Jun-06-22 11:46AM
May-23-22 07:04AM
May-17-22 07:00AM
May-09-22 05:25PM
May-04-22 09:05AM
May-03-22 04:01PM
Apr-29-22 07:00AM
Apr-28-22 01:00AM
Apr-13-22 11:17AM
Apr-05-22 07:00AM
Apr-04-22 04:01PM
Mar-28-22 12:13PM
Mar-08-22 04:01PM
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Posner ChristopherPresident and CEONov 02Sale1.223,7964,631164,411Nov 03 04:37 PM
Posner ChristopherPresident and CEOAug 03Sale3.074,30713,222168,207Aug 04 05:21 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DJun 23Sale3.512,99310,505153,747Jun 27 04:08 PM
Goncalves JoanaChief Medical OfficerJun 23Sale3.512,7239,55853,681Jun 27 04:07 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Jun 23Sale3.512,4838,71588,563Jun 27 04:09 PM
Posner ChristopherPresident and CEOMay 05Sale4.403,86917,024172,514May 09 04:22 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DApr 04Sale4.912,73313,419156,740Apr 06 05:12 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Apr 04Sale4.912,48112,18291,046Apr 06 05:14 PM
Goncalves JoanaChief Medical OfficerApr 04Sale4.912,48112,18256,404Apr 06 05:13 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DMar 03Sale9.716,80266,047159,473Mar 07 04:46 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Mar 03Sale9.716,25660,74693,527Mar 07 04:44 PM
Goncalves JoanaChief Medical OfficerMar 03Sale9.716,22160,40658,885Mar 07 04:43 PM
Posner ChristopherPresident and CEOMar 03Sale9.715,98758,134176,383Mar 07 04:47 PM
Goncalves JoanaChief Medical OfficerFeb 16Sale10.202,26523,10365,106Feb 17 04:27 PM
Posner ChristopherPresident and CEOFeb 02Sale11.804,19149,454182,370Feb 03 06:38 PM
Goncalves JoanaChief Medical OfficerJan 17Sale10.812,26524,48567,371Jan 19 04:18 PM
Goncalves JoanaChief Medical OfficerDec 29Sale10.182,26523,05869,636Jan 03 04:32 PM
Menzaghi Frederique Ph.D.Chief Scientific Off,SVP-R&DDec 21Sale11.273,50639,513166,275Dec 23 04:54 PM
Goncalves JoanaChief Medical OfficerDec 21Sale11.272,99233,72071,901Dec 23 04:53 PM
Terrillion ScottSec'y; Chief Compliance & G.C.Dec 21Sale11.272,56128,86299,783Dec 23 04:52 PM